Thirty Percent of Patients With NSCLC Who Had Actionable Variants Were Not Prescribed Targeted Therapies: Study
The VA NPOP is a program established to provide access to next-generation sequencing for veterans with advanced solid tumors.
Non-Small Cell Lung Cancer
Anti-TIGIT Drug Improved Overall Response Rate, Progression-Free Survival in PD-L1-Selected NSCLC
Updated results confirmed benefit seen in primary analysis.
Opdivo Plus Yervoy Approved for First-Line Treatment of Metastatic NSCLC
The FDA has approved the combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
FoundationOne CDx Approved as Companion Diagnostic for Capmatinib for METex14 NSCLC
The FDA approved FoundationOne CDx as a companion diagnostic for detecting MET with an exon 14-skipping alteration to determine eligibility for capmatinib for NSCLC.
Retevmo Gets Accelerated Approval for RET-Driven Lung, Thyroid Cancers
The FDA has granted accelerated approval to Retevmo™ (selpercatinib; Lilly).
ctDNA Biomarker of Relapse After Resection in Early NSCLC
A ctDNA test identified patients who would develop early relapse after surgical resection of stage I to III NSCLC.
Rates of Treatment-Associated Pneumonitis Higher in Clinical Trials and Real-World Data
Pneumonitis occurred more frequently among patients with NSCLC and a prior history of noninfectious pneumonitis, and with immune checkpoint inhibitors compared with chemotherapy.
Thyroid Dysfunction During Anti–PD‐1 Immunotherapy Linked to Better Survival Outcomes
There was no increase in survival linked to acquired subclinical thyroid dysfunction or preexisting thyroid dysfunction, however.
Study Describes First Mechanism of Resistance to RET Inhibitor Selpercatinib
RET G810 solvent front mutations may be one of the mechanisms behind resistance to selective RET inhibition with the drug selpercatinib, according to a recent study.
Osimertinib-Associated Cardiac Toxicity: A Retrospective Study
The incidence of osimertinib-associated grade 3 or higher cardiac adverse events was 4.9% in a retrospective NSCLC population.
Next post in Lung Cancer
